---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-067871"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:27:11.480772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly

## Summary
- 30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.
- Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).
- Relacorilant well-tolerated; no new safety signals; safety comparable between groups.
- Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.
- Trial enrolled 381 patients globally; biomarker selection not required.

## SEC filing metadata
- accession: 0001193125-25-067871
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/0001193125-25-067871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/d924664d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-067871
- JSON: https://secwatch.observer/filing/0001193125-25-067871.json
- Plain text: https://secwatch.observer/filing/0001193125-25-067871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.